griffithsin
grft
lectin
griffithsia
speci
inhibit
human
immunodefici
replic
subnanomolar
concentr
limit
cellular
toxic
howev
vivo
safeti
grft
fulli
understood
especi
follow
parenter
administr
first
assess
grft
effect
vitro
mous
peripher
blood
mononuclear
cell
mpbmc
viabil
mitogen
activ
use
flowcytometri
well
cytokin
secret
enzymelink
immunosorb
assay
elisa
toxicolog
properti
grft
determin
singl
subcutan
administr
mgkg
daili
dose
mgkg
balbc
mice
context
microbicid
develop
toxic
grft
mgkg
determin
subcutan
intravagin
intraperiton
administr
respect
interestingli
grft
caus
signific
cell
death
mitogen
activ
cytokin
releas
mpbmc
valid
use
mous
model
excel
safeti
profil
grft
obtain
vivo
overt
chang
observ
anim
fit
blood
chemistri
cbc
paramet
follow
grft
treatment
revers
splenomegali
observ
activ
certain
spleen
b
cell
howev
spleen
tissu
patholog
alter
grft
either
singl
high
dose
chronic
dose
final
detect
toxic
found
mucos
system
treatment
mgkg
grft
develop
microbicid
hiv
prevent
despit
recent
advanc
develop
new
antiretrovir
human
immunodefici
viru
hiv
continu
spread
worldwid
astonish
rate
approxim
new
infect
day
hiv
highli
mutabl
viru
thu
major
limit
exist
antiretrovir
abil
hiv
develop
resist
select
pressur
drug
led
drug
design
opt
complementari
combin
high
manufactur
cost
make
deliveri
resourcepoor
area
diseas
burden
often
highest
unfeas
therefor
new
effici
inexpens
antivir
drug
need
order
better
combat
hivaid
year
ago
antihiv
bioassay
guid
fraction
aqueou
extract
evalu
effect
grft
cytokin
releas
mpbmc
cell
treat
h
grft
cultur
supernat
collect
time
point
interleukin
il
beta
il
il
tumor
necrosi
factor
alpha
amount
supernat
assess
enzym
link
immunosorb
assay
elisa
use
specif
elisa
readysetgo
kit
ebiosci
san
diego
ca
usa
follow
manufactur
instruct
experi
cona
phosphatebuff
salin
pb
use
posit
neg
control
respect
previous
describ
cell
viabil
mitogen
experi
cell
cultur
h
presenc
grft
control
analyz
flowcytometr
chang
size
andor
granular
mitogen
propidium
iodid
pi
uptak
cell
death
assess
express
cellular
surfac
activ
marker
flow
cytometri
perform
dual
fluoresc
stain
antimous
antibodi
purchas
bd
bioscienc
tm
san
diego
ca
usa
briefli
cultur
transfer
plate
ml
roundbottom
tube
wash
pb
contain
inactiv
fb
cell
block
purifi
rat
antimous
mous
bd
fc
block
tm
bd
san
jose
ca
usa
min
follow
incub
dark
fluorescein
isothiocyan
fitc
conjug
rat
mab
combin
phycoerythrin
pe
conjug
rat
hamster
mab
min
ice
final
cell
wash
analyz
facscalibur
bd
san
jose
ca
usa
flow
cytometri
data
acquir
analyz
use
cellquest
pro
bd
count
event
per
sampl
cona
pha
use
posit
control
pb
neg
control
six
eight
weekold
femal
balbc
mice
purchas
jackson
laboratori
jax
bar
harbor
usa
anim
hous
filtertop
microisol
cage
temperatureand
humiditycontrol
room
altern
lightdark
cycl
h
standard
mous
diet
water
ad
libitum
experiment
procedur
approv
univers
louisvil
institut
anim
care
use
committe
mice
allow
approxim
one
week
adapt
treatment
first
experi
group
four
anim
inject
either
mgkg
dose
grft
pb
vehicl
day
anim
surviv
behavior
fit
record
one
two
week
anim
euthan
day
parallel
higher
singl
dose
mgkg
grft
administ
mice
divid
three
subgroup
evalu
one
seven
day
posttreat
respect
control
three
group
five
anim
treat
vehicl
pb
next
studi
effect
grft
chronic
administr
two
group
mice
treat
mgkg
grft
pb
daili
basi
day
anim
sacrif
day
nine
mice
per
treatment
group
day
three
per
treatment
group
time
point
respect
experi
blood
collect
immedi
euthanasia
blood
sampl
submit
complet
blood
count
cbc
addit
plasma
sampl
evalu
panel
marker
organ
toxic
use
blood
chemistri
techniqu
euthanasia
spleen
lung
kidney
liver
heart
extract
weigh
case
chronic
treatment
kidney
liver
spleen
tissu
stain
histopatholog
studi
addit
spleen
cell
isol
assess
activ
last
experi
mice
inject
daili
dose
mgkg
grft
pb
vehicl
toxic
assess
measur
bodi
spleen
weight
well
splenocyt
activ
eight
week
old
mice
administ
daili
vagin
applic
grft
formul
carbopol
glycerin
ethylenediaminetetraacet
acid
edta
methylparaben
propylparaben
previous
describ
match
carbopol
placebo
gel
contain
excipi
grft
use
neg
control
intraperiton
treatment
mice
inject
mgkg
grft
pb
volum
vehicl
day
toxic
case
assess
measur
bodi
spleen
weight
well
splenocyt
activ
spleen
cell
isol
accord
wellestablish
procedur
use
ammoniumchloridepotassium
ack
lysi
buffer
remov
red
blood
cell
spleen
tcell
activ
studi
flow
cytometri
describ
mous
pbmc
detect
bcell
activ
studi
similar
fashion
use
dual
fluoresc
stain
antimous
fitcconjug
peconjug
antibodi
purchas
bd
pharmingen
san
jose
ca
usa
kidney
spleen
liver
tissu
collect
anim
treat
daili
dose
mgkg
grft
last
treatment
day
day
week
recoveri
day
fix
neutral
buffer
formalin
paraffinembed
section
stain
hematoxylin
eosin
h
e
stain
evalu
blind
manner
train
pathologist
complet
blood
count
carri
hemavet
hematolog
analyz
drew
scientif
group
inc
dalla
tx
usa
standard
mous
blood
instrument
use
flow
cytometr
techniqu
gener
follow
paramet
potassiumedta
anticoagul
whole
blood
red
blood
cell
rbc
total
differenti
leukocyt
count
neutrophil
lymphocyt
monocyt
eosinophil
basophil
hemoglobin
concentr
hgb
gdl
hematocrit
hct
mean
corpuscular
volum
mcv
fl
mean
cell
hemoglobin
mch
pg
mean
cell
hemoglobin
concentr
mchc
gdl
red
cell
distribut
width
rdw
platelet
plt
mean
platelet
volum
mpv
fl
biochem
analys
perform
use
vettest
chemistri
analyz
idexx
laboratori
inc
atlanta
ga
usa
collect
blood
sampl
use
assess
plasma
level
total
protein
tp
globulin
glob
albumin
alb
blood
urea
nitrogen
bun
creatinin
creat
total
cholesterol
chol
aspartateaminotransferas
ast
alanineaminotransferas
alt
alkalin
phosphatas
alp
amylas
am
total
bilirubin
tbili
blood
glucos
bg
sodium
na
potassium
k
calcium
ca
phosphoru
p
use
reagent
method
provid
idexx
laboratori
inc
atlanta
ga
usa
group
mean
standard
deviat
deriv
bodyand
organweight
hematolog
valu
blood
chemistri
paramet
cytokin
concentr
cell
supernat
cell
defin
region
flowcytogram
statist
signific
assess
oneway
analysi
varianc
anova
student
ttest
unless
otherwis
state
use
graphpad
softwar
san
diego
ca
usa
differ
consid
statist
signific
p
first
evalu
level
four
key
cytokin
includ
mpbmc
cultur
supernat
h
incub
grft
concentr
affect
releas
mous
cell
figur
c
contrast
cona
induc
massiv
cytokin
secret
test
molecul
concentr
depend
manner
figur
case
chang
cytokin
releas
treatment
grft
figur
howev
slight
nonsignific
increas
observ
treatment
grft
initi
transient
effect
notic
h
figur
concentr
elev
treatment
cona
grft
valu
fell
detect
level
similar
pb
treat
cell
figur
data
indic
grft
caus
releas
key
cytokin
chemokin
assess
mous
pbmc
next
assess
effect
grft
mpbmc
size
granular
cultur
presenc
grft
cell
show
differ
flow
cytometri
analysi
compar
pb
treat
cell
wherea
cell
treat
cona
pha
show
subpopul
cell
higher
forward
scatter
fsc
andor
increas
side
scatter
ssc
valu
like
repres
activ
enlarg
pbmc
result
reduct
typic
pbmc
number
gate
figur
e
quantifi
figur
observ
made
even
without
use
fluorophor
likewis
cell
load
propidium
iodid
pi
discrimin
live
dead
cell
flow
cytometri
histogram
mpbmc
treat
grft
similar
obtain
pb
treat
cell
figur
pha
cona
induc
pronounc
cytotox
reflect
shift
histogram
increas
pi
stain
comparison
pbsor
grfttreat
cell
figur
next
assess
effect
grft
mpbmc
size
granular
cultur
presenc
grft
cell
show
differ
flow
cytometri
analysi
compar
pb
treat
cell
wherea
cell
treat
cona
pha
show
subpopul
cell
higher
forward
scatter
fsc
andor
increas
side
scatter
ssc
valu
like
repres
activ
enlarg
pbmc
result
reduct
typic
pbmc
number
gate
figur
e
quantifi
figur
observ
made
even
without
use
fluorophor
likewis
cell
load
propidium
iodid
pi
discrimin
live
dead
cell
flow
cytometri
histogram
mpbmc
treat
grft
similar
obtain
pb
treat
cell
figur
pha
cona
induc
pronounc
cytotox
reflect
shift
histogram
increas
pi
stain
comparison
pbsor
grfttreat
cell
figur
next
assess
effect
grft
mpbmc
size
granular
cultur
presenc
grft
cell
show
differ
flow
cytometri
analysi
compar
pb
treat
cell
wherea
cell
treat
cona
pha
show
subpopul
cell
higher
forward
scatter
fsc
andor
increas
side
scatter
ssc
valu
like
repres
activ
enlarg
pbmc
result
reduct
typic
pbmc
number
gate
figur
e
quantifi
figur
observ
made
even
without
use
fluorophor
likewis
cell
load
propidium
iodid
pi
discrimin
live
dead
cell
flow
cytometri
histogram
mpbmc
treat
grft
similar
obtain
pb
treat
cell
figur
pha
cona
induc
pronounc
cytotox
reflect
shift
histogram
increas
pi
stain
comparison
pbsor
grfttreat
cell
figur
furthermor
evalu
percentag
cell
express
two
known
pbmc
cellular
activ
marker
pbstreat
cell
cell
figur
mpbmc
incub
presenc
grft
show
similar
valu
cell
respect
wherea
amount
markedli
increas
nm
ie
pha
cona
shown
figur
total
number
cell
express
compar
statist
signific
differ
pbstreat
cell
cultur
presenc
grft
figur
contrast
cell
express
treatment
pha
cona
respect
figur
similar
observ
made
surfac
activ
marker
shown
figur
treatment
grft
result
pbmc
respect
valu
significantli
differ
obtain
pbstreat
cell
howev
consider
increas
popul
mous
pbmc
observ
treatment
pha
cona
addit
total
percentag
cell
similar
unstimul
pb
treat
cell
grft
respect
shown
figur
mpbmc
stimul
pha
result
cell
wherea
cona
treatment
yield
cell
express
figur
taken
togeth
find
indic
good
safeti
profil
mpbmc
furthermor
evalu
percentag
cell
express
two
known
pbmc
cellular
activ
marker
pbstreat
cell
cell
figur
mpbmc
incub
presenc
grft
show
similar
valu
cell
respect
wherea
amount
markedli
increas
nm
ie
pha
cona
shown
figur
total
number
cell
express
compar
statist
signific
differ
pbstreat
cell
cultur
presenc
grft
figur
contrast
cell
express
treatment
pha
cona
respect
figur
similar
observ
made
surfac
activ
marker
shown
figur
treatment
grft
result
pbmc
respect
valu
significantli
differ
obtain
pbstreat
cell
howev
consider
increas
popul
mous
pbmc
observ
treatment
pha
cona
addit
total
percentag
cell
similar
unstimul
pb
treat
cell
grft
respect
shown
figur
mpbmc
stimul
pha
result
cell
wherea
cona
treatment
yield
cell
express
figur
taken
togeth
find
indic
good
safeti
profil
mpbmc
preliminari
studi
mice
inject
singl
subcutan
sc
dose
mgkg
grft
anim
surviv
treatment
two
week
observ
period
behavior
movement
activ
groom
similar
mice
treat
pb
vehicl
anim
fit
evalu
use
bodi
weight
surrog
marker
one
two
week
treatment
grft
group
show
compar
bodi
weight
control
anim
figur
organ
toxic
assess
studi
measur
organ
weight
sacrific
heart
lung
liver
preliminari
studi
mice
inject
singl
subcutan
sc
dose
mgkg
grft
anim
surviv
treatment
two
week
observ
period
behavior
movement
activ
groom
similar
mice
treat
pb
vehicl
anim
fit
evalu
use
bodi
weight
surrog
marker
one
two
week
treatment
grft
group
show
compar
bodi
weight
control
anim
figur
organ
toxic
assess
studi
measur
organ
weight
sacrific
heart
lung
liver
kidney
affect
grft
administr
data
shown
spleentobodi
weight
ratio
slightli
elev
two
week
treatment
mgkg
grft
vs
pb
differ
signific
figur
sinc
observ
harm
effect
singl
dose
mgkg
vivo
interest
evalu
potenti
toxic
singl
sc
inject
higher
dose
mgkg
grft
mice
surviv
rate
experi
anim
treat
mgkg
grft
show
chang
behavior
bodi
weight
figur
find
suggest
singl
dose
grft
mgkg
caus
massiv
toxic
inject
mice
mice
euthan
one
seven
day
post
treatment
timepoint
heart
lung
liver
kidney
weight
unaffect
presenc
grft
data
shown
howev
spleen
size
weight
increas
anim
sacrif
one
day
post
treatment
mean
spleen
bodi
weight
ratio
grfttreat
mice
vs
pb
group
figur
although
decreas
splenomegali
persist
one
week
treatment
ratio
grft
pb
group
respect
figur
interestingli
grfttreat
anim
spleen
compar
size
weight
pb
group
two
week
recoveri
ratio
grft
anim
pb
control
shown
figur
blood
chemistri
paramet
mice
reveal
signific
treatmentrel
differ
grft
control
group
likewis
function
kidney
bun
cre
pancrea
ami
glu
immun
system
glob
indic
liver
function
alb
tbil
alt
advers
affect
grft
treatment
tabl
howev
nonsignific
increas
observ
alp
level
sampl
collect
one
week
grft
treatment
arbitrari
unit
au
vs
au
pb
control
p
two
week
administr
trend
observ
au
record
grft
group
au
pb
treat
anim
p
furthermor
blood
chemistri
profil
reveal
effect
grft
nutrit
statu
tp
calcium
ca
phosphor
pho
plasma
sodium
na
tabl
howev
nonsignific
increas
notic
cholesterol
amount
mgdl
grfttreat
anim
compar
mgdl
found
control
group
p
two
week
recoveri
tabl
blood
sampl
submit
complet
blood
count
cbc
signific
variat
hematolog
profil
due
grft
treatment
inde
valu
obtain
cbc
white
blood
cell
total
leucocyt
ne
ly
mo
eo
ba
erythrocyt
total
count
hgb
hct
mcv
mch
mchc
rdw
platelet
total
count
mean
platelet
volum
similar
grftand
pbstreat
group
tabl
fourteen
daili
dose
mgkg
grft
inject
sc
mice
control
group
receiv
pb
vehicl
mice
surviv
treatment
anim
behavior
similar
grft
pb
treatment
group
throughout
experi
fit
determin
anim
bodi
weight
unchang
treatment
grft
figur
addit
chang
lung
kidney
liver
heart
weight
grft
treatment
data
shown
howev
splenomegali
observ
sacrific
day
spleenbodi
weight
ratio
grft
control
group
respect
figur
interestingli
splenomegali
decreas
consider
two
day
recoveri
spleentobodi
weight
ratio
anim
treat
grft
vs
pb
group
p
seven
day
post
treatment
differ
spleenbodi
ratio
signific
grft
pb
group
respect
p
shown
figur
note
histolog
studi
kidney
liver
collect
day
reveal
observ
patholog
induc
grft
data
shown
despit
splenomegali
observ
advers
patholog
due
grft
treatment
spleen
tissu
h
e
stain
repres
spleen
shown
figur
c
interestingli
segment
margin
zone
lymphoid
deplet
occasion
observ
across
group
regardless
treatment
order
studi
whether
splenomegali
due
spleen
band
tlymphocyt
activ
mice
treat
day
mgkg
grft
rel
pbstreat
anim
found
posit
splenocyt
markedli
increas
grft
group
day
rel
pb
cell
p
differ
vanish
week
recoveri
figur
interestingli
differ
rel
amount
cell
stain
posit
splenocyt
obtain
pb
grft
anim
either
time
point
figur
shown
figur
cell
express
tcell
activ
marker
slightli
abund
anim
treat
grft
rel
pb
group
p
day
day
differ
markedli
reduc
rel
pb
treat
mice
p
likewis
spleen
cell
express
slightli
increas
daili
treatment
grft
rel
pb
p
differ
reduc
recoveri
rel
pb
p
next
conduct
blood
chemistri
studi
observ
differ
due
chronic
treatment
grft
nearli
paramet
includ
alb
bun
creat
tbili
alt
am
bg
glob
tp
ca
p
na
tabl
observ
singl
dose
mgkg
grft
chol
level
elev
reach
mgdl
day
control
pb
mgdl
p
week
recoveri
sharp
decreas
cholesterol
level
grfttreat
anim
although
differ
still
statist
signific
compar
control
group
tabl
addit
alp
level
increas
consequ
grft
treatment
rel
pb
treatment
group
set
evalu
day
day
slight
decreas
level
remain
higher
grft
group
tabl
cbc
data
reveal
minim
treatmentrel
differ
grft
control
group
valu
obtain
red
blood
cell
total
count
hemoglobin
concentr
hematocrit
mean
corpuscular
volum
mean
cell
hemoglobin
mean
cell
hemoglobin
concentr
red
cell
distribut
width
platelet
total
count
mean
platelet
volum
similar
treatment
group
timepoint
tabl
notic
differ
total
leukocyt
count
due
grft
treatment
howev
observ
increas
neutrophil
number
day
grft
group
vs
pb
control
group
nevertheless
differ
statist
signific
assess
twotail
unpair
ttest
welch
correct
meanwhil
decreas
lymphocyt
number
notic
grft
group
vs
control
valu
fell
within
expect
rang
describ
mice
shown
tabl
mo
eo
ba
number
unchang
notabl
hematolog
profil
anim
seven
day
posttreat
similar
grft
pb
group
taken
togeth
find
indic
good
safeti
profil
grft
murin
model
parenter
administr
erythrocyt
rbc
previou
studi
shown
intravagin
dose
mgkg
grft
abl
inhibit
anticip
similar
dose
use
case
mucos
prevent
therefor
evalu
toxic
mgkg
grft
intravagin
administr
also
interest
assess
toxic
mgkg
grft
administ
system
ie
subcutan
intraperiton
determin
potenti
advers
effect
grft
case
absorpt
shown
figur
anim
display
similar
bodi
weight
throughout
experi
whether
treat
grft
pb
regardless
administr
rout
observ
made
rel
spleen
weight
figur
accord
result
activ
spleen
bor
tcell
found
grft
administr
regardless
rout
evalu
use
marker
respect
figur
result
demonstr
grft
excel
safeti
profil
microbicid
figur
anim
display
similar
bodi
weight
throughout
experi
whether
treat
grft
pb
regardless
administr
rout
observ
made
rel
spleen
weight
figur
accord
result
activ
spleen
bor
tcell
found
grft
administr
regardless
rout
evalu
use
marker
respect
figur
result
demonstr
grft
excel
safeti
profil
microbicid
valid
use
murin
model
evalu
toxicolog
effect
grft
pmbc
purifi
mous
blood
sampl
light
data
describ
previou
work
human
pbmc
cervicovagin
cell
line
shown
purifi
mpbmc
moder
affect
high
concentr
grft
term
viabil
mitogen
addit
amount
mpbmc
cultur
supernat
alter
grft
concentr
concentr
affect
grft
although
transient
moder
increas
observ
treatment
one
day
treatment
data
indic
grft
boost
releas
four
cytokin
mpbmc
figur
safeti
chronic
dose
mgkg
grft
mice
mous
bodi
spleen
b
weight
assess
daili
sc
intravagin
intraperiton
administr
respect
grft
mgkg
pb
addit
immun
cell
activ
splenocyt
mice
evalu
flow
cytometri
dual
fluoresc
stain
fitcconjug
mab
combin
respect
peconjug
c
cell
stain
posit
singl
posit
ttotal
repres
singl
posit
doubl
posit
valid
use
murin
model
evalu
toxicolog
effect
grft
pmbc
purifi
mous
blood
sampl
light
data
describ
previou
work
human
pbmc
cervicovagin
cell
line
shown
purifi
mpbmc
moder
affect
high
concentr
grft
term
viabil
mitogen
addit
amount
mpbmc
cultur
supernat
alter
grft
concentr
concentr
affect
grft
although
transient
moder
increas
observ
treatment
one
day
treatment
data
indic
grft
boost
releas
four
cytokin
mpbmc
corrobor
previou
observ
lectin
induc
minim
chang
secret
cytokin
chemokin
human
pbmc
assess
multiplex
immunoassay
collect
find
suggest
mous
valid
model
toxicolog
assess
grft
mice
surviv
singl
treatment
mgkg
daili
treatment
mgkg
grft
addit
grft
treatment
relat
advers
effect
behavior
fit
bodyweight
gain
loss
observ
find
suggest
grft
caus
massiv
toxic
mice
parenter
administr
note
amount
protein
use
experi
high
sinc
aim
record
maxim
effect
lectin
could
trigger
adult
mice
recent
demonstr
grft
toler
minim
toxic
juvenil
guinea
pig
subcutan
administr
daili
dose
mgkg
lectin
also
studi
mice
effect
parenter
administr
instanc
attempt
determin
welltoler
dose
mice
cyanovirinn
cvn
inject
beneath
skin
upper
back
daili
dose
mgkg
caus
weight
loss
mice
dose
mgkg
lower
caus
sign
ill
data
reveal
grft
treatmentrel
toxic
effect
lung
liver
kidney
heart
evalu
organ
weight
andor
histolog
howev
revers
splenomegali
observ
mice
treat
singl
high
dose
mgkg
chronic
mgkg
grft
studi
involv
phaseolu
vulgari
lectin
reveal
parenter
administr
carbohydr
bind
protein
affect
extraintestin
organ
suckl
rat
inde
shown
liver
spleen
weight
increas
anim
treat
parenter
phytohemagglutinin
author
suggest
chang
organ
weight
result
immunolog
cleansingrespons
process
organ
respons
circul
pha
sc
administr
plausibl
observ
splenomegali
case
grft
reflect
nascent
immun
reaction
anim
well
shown
posit
splenocyt
elev
daili
treatment
grft
mgkg
differ
obtain
week
recoveri
recent
subset
murin
splenic
cell
express
lack
describ
murakami
collabor
propos
involv
format
follicular
dendrit
cell
network
play
critic
role
immun
reaction
foreign
antigen
unclear
whether
cell
increas
grft
treatment
function
model
addit
express
cell
slightli
abund
chronic
treatment
mgkg
grft
studi
effect
reduc
recoveri
period
effect
spleen
size
remain
controversi
demonstr
induct
tcell
earli
activ
marker
mice
result
mark
splenomegali
knockout
mous
spleen
shown
enlarg
compar
wt
mice
tumor
collageninduc
arthriti
challeng
model
subtl
toxic
indirectli
assess
evalu
effect
drug
plasma
concentr
blood
chemistri
marker
differ
observ
cholesterol
level
increas
result
singl
mgkg
chronic
mgkg
dose
grft
howev
differ
vehicl
grft
group
sharpli
reduc
recoveri
shown
suggest
splenomegali
could
result
increas
uptak
unesterifi
chol
circul
lipid
splenic
macrophag
case
studi
year
old
man
present
homogen
enlarg
spleen
elev
serum
total
cholesterol
despit
observ
increas
plasma
chol
level
grft
administr
clear
whether
high
chol
level
respons
describ
spleen
enlarg
vice
versa
insuffici
data
correl
two
anomali
chronic
treatment
mgkg
grft
elev
alp
observ
differ
control
treatment
reduc
recoveri
recent
report
similar
find
grft
treat
guinea
pig
normal
adult
serum
mainli
contain
livertyp
alp
small
variabl
amount
intestin
bone
enzym
point
unclear
whether
increas
alp
level
observ
reflect
liver
toxic
inde
chang
record
marker
liver
toxic
assess
includ
alb
tbili
alp
importantli
improv
spleen
enlarg
splenocyt
activ
chol
alp
level
occur
day
posttreat
indic
even
high
level
grft
caus
irrepar
damag
spleen
anim
whole
find
suggest
therapeut
set
might
appropri
administ
drug
longer
time
interv
eg
everi
day
twice
weekli
weekli
rather
daili
inject
dose
mgkg
maintain
shown
intravagin
mgkg
grft
inhibit
similar
dose
would
use
mucos
prevent
shown
grft
dose
caus
detect
toxic
mice
intravagin
treatment
although
unlik
grft
absorb
mucos
surfac
intravagin
administr
healthi
subject
possibl
drug
get
circul
individu
suffer
ulcer
std
inde
wide
accept
std
import
risk
factor
hiv
vice
versa
therefor
assess
effect
mgkg
grft
deliv
intraperiton
subcutan
administr
respect
advers
effect
found
either
case
result
confirm
grft
excel
safeti
profil
microbicid
candid
previous
shown
use
differ
system
interestingli
grft
recent
shown
significantli
protect
genit
herp
mous
model
meanwhil
combin
grft
carrageenan
display
potent
antivir
effect
mice
infect
human
papillomaviru
hpv
find
support
develop
grft
microbicid
prevent
hivaid
suscept
envelop
virus
summari
result
indic
excel
safeti
profil
grft
murin
model
present
show
outstand
safeti
properti
lectin
vivo
vitro
therefor
grft
develop
microbicid
prevent
hivaid
addit
lectin
could
becom
power
weapon
fight
bloodborn
envelop
virus
gener
consid
treatment
aid
well
administ
via
parenter
rout
supplementari
materi
follow
avail
onlin
figur
effect
grft
mpbmc
death
tabl
effect
singl
subcutan
dose
mgkg
grft
blood
chemistri
paramet
tabl
effect
singl
subcutan
dose
mgkg
grft
mous
hematolog
profil
